Compare Stocks: VVOS, NDRA, SONX, and NVNO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NDRA ENDRA Life Sciences	$4.77 -5.4%	$5.39	$2.96 ▼ $8.00	$7.24M	-0.09	56,324 shs	11,301 shs
NVNO enVVeno Medical	$7.31 -8.3%	$9.92	$7.01 ▼ $28.70	$5.08M	1.29	19,178 shs	14,086 shs
SONX Sonendo	$1.28	$1.08	$0.02 ▼ $1.90	$6.11M	1.86	1,247 shs	N/A
VVOS Vivos Therapeutics	$0.14 -1.8%	$0.21	$0.13 ▼ $3.28	$1.93M	6.11	4.73 million shs	393,357 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NDRA ENDRA Life Sciences	-1.95%	-16.56%	-10.32%	-10.16%	-37.93%
NVNO enVVeno Medical	-2.21%	-3.10%	-24.02%	-25.93%	-69.27%
SONX Sonendo	0.00%	+28.00%	-1.54%	+56.10%	+220.00%
VVOS Vivos Therapeutics	-1.80%	-7.87%	-21.33%	-65.71%	-95.53%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NDRA ENDRA Life Sciences	$4.77 -5.4%	$5.39	$2.96 ▼ $8.00	$7.24M	-0.09	56,324 shs	11,301 shs
NVNO enVVeno Medical	$7.31 -8.3%	$9.92	$7.01 ▼ $28.70	$5.08M	1.29	19,178 shs	14,086 shs
SONX Sonendo	$1.28	$1.08	$0.02 ▼ $1.90	$6.11M	1.86	1,247 shs	N/A
VVOS Vivos Therapeutics	$0.14 -1.8%	$0.21	$0.13 ▼ $3.28	$1.93M	6.11	4.73 million shs	393,357 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NDRA ENDRA Life Sciences	-1.95%	-16.56%	-10.32%	-10.16%	-37.93%
NVNO enVVeno Medical	-2.21%	-3.10%	-24.02%	-25.93%	-69.27%
SONX Sonendo	0.00%	+28.00%	-1.54%	+56.10%	+220.00%
VVOS Vivos Therapeutics	-1.80%	-7.87%	-21.33%	-65.71%	-95.53%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NDRA ENDRA Life Sciences	2.00	Hold	$25.00	423.45% Upside
NVNO enVVeno Medical	2.33	Hold	N/A	N/A
SONX Sonendo	0.00	N/A	N/A	N/A
VVOS Vivos Therapeutics	2.25	Hold	$2.80	1,914.39% Upside

Current Analyst Ratings Breakdown

Latest VVOS, NDRA, SONX, and NVNO Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/28/2026	NDRA ENDRA Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/25/2026	NVNO enVVeno Medical	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/10/2026	NDRA ENDRA Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	NDRA ENDRA Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
7/31/2026	NDRA ENDRA Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	NDRA ENDRA Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
7/17/2026	VVOS Vivos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NDRA ENDRA Life Sciences	N/A	N/A	N/A	N/A	$1.92 per share	N/A
NVNO enVVeno Medical	N/A	N/A	N/A	N/A	$41.38 per share	N/A
SONX Sonendo	$44.40M	0.14	N/A	N/A	$89.42 per share	0.01
VVOS Vivos Therapeutics	$17.44M	0.11	N/A	N/A	($0.16) per share	-0.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NDRA ENDRA Life Sciences	-$7.03M	-$6.38	N/A	N/A	N/A	N/A	-246.34%	-150.81%	11/13/2026 (Estimated)
NVNO enVVeno Medical	-$19.47M	-$19.33	N/A	N/A	N/A	N/A	-62.28%	-56.83%	10/30/2026 (Estimated)
SONX Sonendo	-$60.92M	-$71.12	N/A	N/A	N/A	-92.74%	-184.01%	-68.60%	11/11/2026 (Estimated)
VVOS Vivos Therapeutics	-$21.17M	-$1.90	N/A	N/A	N/A	-122.00%	-2,325.64%	-102.01%	11/18/2026 (Estimated)

Latest VVOS, NDRA, SONX, and NVNO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	N/A	SONX Sonendo	-$118.00	N/A	N/A	N/A	$7.79 million	N/A
10/30/2026	N/A	NVNO enVVeno Medical	-$3.27	N/A	N/A	N/A	$2.25 million	N/A
8/14/2026	Q2 2026	NDRA ENDRA Life Sciences	-$0.84	-$0.63	+$0.21	$0.06	$0.10 million	N/A
8/14/2026	Q2 2026	VVOS Vivos Therapeutics	-$0.41	-$0.31	+$0.10	-$0.31	$5.63 million	$5.15 million
7/30/2026	Q2 2026	NVNO enVVeno Medical	-$4.69	-$5.37	-$0.68	-$5.37	$1.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
NDRA ENDRA Life Sciences	N/A	N/A	N/A	N/A	N/A
NVNO enVVeno Medical	N/A	N/A	N/A	N/A	N/A
SONX Sonendo	N/A	N/A	N/A	N/A	N/A
VVOS Vivos Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NDRA ENDRA Life Sciences	N/A	7.10	7.10
NVNO enVVeno Medical	N/A	11.70	11.70
SONX Sonendo	0.55	1.82	1.22
VVOS Vivos Therapeutics	N/A	0.21	0.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NDRA ENDRA Life Sciences	1.19%
NVNO enVVeno Medical	34.71%
SONX Sonendo	28.68%
VVOS Vivos Therapeutics	26.35%

Insider Ownership

Company	Insider Ownership
NDRA ENDRA Life Sciences	10.00%
NVNO enVVeno Medical	15.00%
SONX Sonendo	7.90%
VVOS Vivos Therapeutics	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NDRA ENDRA Life Sciences	11	1.50 million	1.35 million	Not Optionable
NVNO enVVeno Medical	33	690,000	591,000	No Data
SONX Sonendo	250	4.78 million	393,000	Not Optionable
VVOS Vivos Therapeutics	268	13.90 million	13.60 million	Optionable

VVOS, NDRA, SONX, and NVNO Headlines

Recent News About These Companies

Vivos Therapeutics targets $3.6 million in annual cost reductions as revenue growth initiatives accelerate

September 29, 2026 | msn.com

Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives

September 29, 2026 | globenewswire.com

Vivos Therapeutics Announces Material Debt Reduction

September 8, 2026 | globenewswire.com

Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference

September 1, 2026 | newsfilecorp.comN

Vivos Therapeutics Advances South Florida Sleep Center With South Palm Cardiovascular Partnership

August 28, 2026 | rttnews.com

Vivos Therapeutics Announces Definitive Agreements With South Palm Cardiovascular Associates to Launch South Florida Sleep & Airway Medicine Center

August 28, 2026 | quiverquant.comQ

Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center

August 28, 2026 | globenewswire.com

Vivos Therapeutics Reports 212% Increase in Nevada Sleep & Airway Medicine Center Referrals Ahead of Henderson Facility Opening

August 25, 2026 | quiverquant.comQ

Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers

August 25, 2026 | globenewswire.com

Vivos Therapeutics Opens New Henderson Sleep Center, Expects Capacity to More Than Double to Over $10 Million Annually

August 20, 2026 | quiverquant.comQ

Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment

August 20, 2026 | globenewswire.com

Vivos Therapeutics shares slide after Q2 revenue falls short of forecasts

August 17, 2026 | msn.com

Vivos Therapeutics, Inc: Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update

August 15, 2026 | finanznachrichten.de

Vivos Therapeutics, Inc. (VVOS) Q2 2026 Earnings Call Transcript

August 14, 2026 | seekingalpha.com

Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates

August 14, 2026 | zacks.com

Vivos Therapeutics Reports 35% Quarterly Revenue Growth, Rising Patient Demand and Second Quarter 2026 Results

August 14, 2026 | quiverquant.comQ

Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update

August 14, 2026 | globenewswire.com

Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call

August 14, 2026 | globenewswire.com

Vivos Therapeutics Expands Greenway Health Partnership to Deploy AI-Enabled Platform Across All Clinical and Revenue Operations

August 11, 2026 | markets.businessinsider.com

Vivos Therapeutics Expands AI Workflow Partnership with Greenway Health, Citing Up to $9.1 Million in Annual Value at Sleep Centers of Nevada

August 11, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

VVOS, NDRA, SONX, and NVNO Company Descriptions

ENDRA Life Sciences NASDAQ:NDRA

$4.77 -0.27 (-5.36%)

As of 02:26 PM Eastern

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

enVVeno Medical NASDAQ:NVNO

$7.30 -0.67 (-8.34%)

As of 02:27 PM Eastern

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

Sonendo NYSE:SONX

$1.28 0.00 (0.00%)

As of 10/13/2026

Sonendo, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes devices for root canal therapy in the United States and Canada. It provides GentleWave, a tooth decay treatment, a technology platform designed for cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The company also offers SoundSeal, a material used to build and create a sealing platform on the top of the crown; and Sonendo-branded liquid solution of ethylenediaminetetraacetic acid EDTA that is used to help debride and disinfect the root canal system. In addition, it provides The Digital Office, a practice management software to enable an integrated digital office for dental practitioners. The company was formerly known as Dentatek Corporation and changed its name to Sonendo, Inc. in March 2011. The company was incorporated in 2006 and is headquartered in Laguna Hills, California.

Vivos Therapeutics NASDAQ:VVOS

$0.14 0.00 (-1.84%)

As of 02:26 PM Eastern

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VVOS, NDRA, SONX, and NVNO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VVOS, NDRA, SONX, and NVNO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VVOS, NDRA, SONX, and NVNO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VVOS, NDRA, SONX, and NVNO Company Descriptions

ENDRA Life Sciences NASDAQ:NDRA

enVVeno Medical NASDAQ:NVNO

Sonendo NYSE:SONX

Vivos Therapeutics NASDAQ:VVOS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VVOS, NDRA, SONX, and NVNO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VVOS, NDRA, SONX, and NVNO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VVOS, NDRA, SONX, and NVNO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VVOS, NDRA, SONX, and NVNO Company Descriptions

ENDRA Life Sciences NASDAQ:NDRA

enVVeno Medical NASDAQ:NVNO

Sonendo NYSE:SONX

Vivos Therapeutics NASDAQ:VVOS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools